Choice Institutional Equities's report on Rainbow Childrens Medicare
Strategic network expansion via the hub-and-spoke model, deeper entry into new markets and a sharper emphasis on tertiary and quaternary care should reinforce growth trajectory. Additionally, continued scaling up of the IVF vertical is expected to further support strong and sustainable long-term growth.
Outlook
We forecast Revenue/EBITDA/PAT to expand at a CAGR of 17.7%/19.5%/28.2% over FY25–FY28E. Valuing the stock at an EV/EBITDA multiple of 22x (maintained) on the average of FY27–FY28E, we revise our target price of INR 1,580 and maintain our rating to ‘BUY.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
